Contineum Therapeutics (CTNM) FDA Approvals $11.88 +0.02 (+0.17%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$11.85 -0.03 (-0.25%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Contineum Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Contineum Therapeutics (CTNM). Over the past two years, Contineum Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PIPE-307. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. PIPE-307 FDA Regulatory Events PIPE-307 is a drug developed by Contineum Therapeutics for the following indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Top-line data - November 20,2025Top-Line Data Phase 2Drug: PIPE-307Announced Date: November 20, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc. today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics reported topline results from the Phase 2 VISTA trial of PIPE-307, a selective M1 receptor antagonist being developed for relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile at both doses tested. However, the study did not meet its prespecified primary or secondary efficacy endpoints. In particular, there was no significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms, a key clinical measure used in the trial. The randomized, double-blind, placebo-controlled, multi-center proof-of-concept trial included clinical and imaging endpoints. Contineum said it will continue to analyze exploratory endpoint data and plans to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal. The company remains committed to learning from these data as it advances its neuroscience and immunology programs.Read AnnouncementEnrollment Update - January 8,2025Enrollment Update Phase 2Drug: PIPE-307Announced Date: January 8, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics announced a major milestone in its Phase 2 PIPE-307 VISTA trial, achieving the targeted enrollment of 168 patients with relapsing-remitting multiple sclerosis (RRMS). The trial is studying a potentially first-in-class M1 receptor antagonist designed to promote remyelination and offer a new treatment approach for RRMS patients. This is a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study that will assess both safety and effectiveness by measuring several clinical and imaging endpoints sensitive to changes in remyelination. The company expects the last patient to complete the trial in the third quarter of 2025. Contineum Therapeutics believes that the success of the PIPE-307 trial could lead to a breakthrough in the treatment of RRMS, potentially ushering in the next evolution in therapy for these patients.Read Announcement Contineum Therapeutics FDA Events - Frequently Asked Questions Has Contineum Therapeutics received FDA approval? As of now, Contineum Therapeutics (CTNM) has not received any FDA approvals for its therapy in the last two years. What drugs has Contineum Therapeutics submitted to the FDA? In the past two years, Contineum Therapeutics (CTNM) has reported FDA regulatory activity for PIPE-307. What is the most recent FDA event for Contineum Therapeutics? The most recent FDA-related event for Contineum Therapeutics occurred on November 20, 2025, involving PIPE-307. The update was categorized as "Top-line data," with the company reporting: "Contineum Therapeutics, Inc. today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS)." What conditions do Contineum Therapeutics' current drugs treat? Currently, Contineum Therapeutics has one therapy (PIPE-307) targeting the following condition: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events BioCryst Pharmaceuticals FDA EventsCogent Biosciences FDA EventsJazz Pharmaceuticals FDA EventsKymera Therapeutics FDA EventsAbbVie FDA EventsAC Immune FDA EventsAscendis Pharma A/S FDA EventsC4 Therapeutics FDA EventsCompugen FDA EventsCellectis FDA EventsClimb Bio FDA EventsCaribou Biosciences FDA EventsAlpha Tau Medical FDA EventsGuardant Health FDA EventsGenmab A/S FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Mesoblast FDA Events Recursion Pharmaceuticals FDA Events Harmony Biosciences FDA Events Stoke Therapeutics FDA Events AbCellera Biologics FDA Events Iovance Biotherapeutics FDA Events Ocular Therapeutix FDA Events Lakefront Biotherapeutics American Depositary Shares FDA Events Intellia Therapeutics FDA Events Zymeworks FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:CTNM last updated on 11/21/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Top-line data - November 20,2025Top-Line Data Phase 2Drug: PIPE-307Announced Date: November 20, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc. today reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, in development for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics reported topline results from the Phase 2 VISTA trial of PIPE-307, a selective M1 receptor antagonist being developed for relapsing-remitting multiple sclerosis (RRMS). The trial showed that PIPE-307 had an acceptable safety and tolerability profile at both doses tested. However, the study did not meet its prespecified primary or secondary efficacy endpoints. In particular, there was no significant change in binocular 2.5% low contrast letter acuity (LCLA) across treatment arms, a key clinical measure used in the trial. The randomized, double-blind, placebo-controlled, multi-center proof-of-concept trial included clinical and imaging endpoints. Contineum said it will continue to analyze exploratory endpoint data and plans to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal. The company remains committed to learning from these data as it advances its neuroscience and immunology programs.Read Announcement
Enrollment Update - January 8,2025Enrollment Update Phase 2Drug: PIPE-307Announced Date: January 8, 2025Indication: For the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)AnnouncementContineum Therapeutics, Inc announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).AI SummaryContineum Therapeutics announced a major milestone in its Phase 2 PIPE-307 VISTA trial, achieving the targeted enrollment of 168 patients with relapsing-remitting multiple sclerosis (RRMS). The trial is studying a potentially first-in-class M1 receptor antagonist designed to promote remyelination and offer a new treatment approach for RRMS patients. This is a randomized, double-blind, placebo-controlled, multi-center proof-of-concept study that will assess both safety and effectiveness by measuring several clinical and imaging endpoints sensitive to changes in remyelination. The company expects the last patient to complete the trial in the third quarter of 2025. Contineum Therapeutics believes that the success of the PIPE-307 trial could lead to a breakthrough in the treatment of RRMS, potentially ushering in the next evolution in therapy for these patients.Read Announcement
Free CTNM Stock Alerts